Get the Stockscreener App
32.40
0.59%
0.19
After Hours:
32.40
Veracyte Inc stock is traded at $32.40, with a volume of 637.99K.
It is up +0.59% in the last 24 hours and down -11.45% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$32.21
Open:
$32.305
24h Volume:
637.99K
Relative Volume:
0.71
Market Cap:
$2.57B
Revenue:
$517.15M
Net Income/Loss:
$66.35M
P/E Ratio:
39.45
EPS:
0.8212
Net Cash Flow:
$126.63M
1W Performance:
-1.19%
1M Performance:
-11.45%
6M Performance:
-10.52%
1Y Performance:
+9.61%
1-Day Range:
$32.00
$33.54
1-Week Range:
$29.45
$33.54
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
32.40 | 2.56B | 517.15M | 66.35M | 126.63M | 0.8212 |
TMO
Thermo Fisher Scientific Inc
|
494.54 | 182.60B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.79 | 134.18B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
564.66 | 44.63B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.54 | 32.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.89 | 29.21B | 3.17B | 642.63M | 516.49M | 10.77 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte (VCYT): Needham Reaffirms "Buy" Rating with $48 Price T - GuruFocus
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Needham reiterates Veracyte stock rating on bladder cancer test plans - investing.com
Cathie Wood’s ARK buys OpenAI Group stock, sells Veracyte shares By Investing.com - Investing.com India
Cathie Wood’s ARK buys OpenAI Group stock, sells Veracyte shares - Investing.com
Is Veracyte Stock a Smart Addition to Your Investment Portfolio at This Time? - bitget.com
Is Veracyte Stock the Right Pick for Your Portfolio Now? - Yahoo Finance Singapore
MACD Signal: Is Veracyte Inc stock a value trap2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
VCYT SEC FilingsVeracyte 10-K, 10-Q, 8-K Forms - Stock Titan
Veracyte price target lowered to $45 from $50 at Guggenheim - TipRanks
Exit Recap: Is Veracyte Inc a strong candidate for buy and hold2026 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Guggenheim Maintains Buy Rating, Lowers Price Target on VCYT to $45 | VCYT Stock News - GuruFocus
Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN
Veracyte (NASDAQ:VCYT) Price Target Lowered to $45.00 at Guggenheim - MarketBeat
Guggenheim Maintains Veracyte(VCYT.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
Does Veracyte (NASDAQ:VCYT) Deserve A Spot On Your Watchlist? - Moomoo
Veracyte (NASDAQ:VCYT) Shares Down 9.2%What's Next? - MarketBeat
Vanguard disaggregates reporting; lists zero holdings in Veracyte (VCYT) - Stock Titan
Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Volatility Watch: Is Veracyte Inc stock a top performer YTDPortfolio Return Report & Expert Approved Trade Ideas - baoquankhu1.vn
Veracyte, Inc. $VCYT Shares Sold by Nordea Investment Management AB - MarketBeat
Veracyte, Inc. $VCYT Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Update Report: Should value investors consider Veracyte Inc2026 Trade Ideas & Weekly High Return Forecasts - baoquankhu1.vn
Veracyte (VCYT) Chief Dev and Tech Officer files initial Form 3 - Stock Titan
Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares - Sahm
TGI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Westview Management dba Westview Investment Advisors Invests $1.38 Million in Veracyte, Inc. $VCYT - MarketBeat
Does Veracyte (VCYT) offer both strength and opportunity? - MSN
Veracyte Names Kevin Haas as Chief Development and Technology Officer - StreetInsider
Breakouts Watch: Can Veracyte Inc expand into new marketsQuarterly Growth Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story - simplywall.st
Veracyte appoints Kevin Haas as chief development officer By Investing.com - Investing.com Australia
Veracyte CFO Chambers sells $662k in VCYT stock - Investing.com Nigeria
Veracyte (VCYT) Appoints New Chief Development and Technology Of - GuruFocus
Veracyte names Kevin Haas as Chief Development and Technology Officer - TipRanks
Veracyte names Kevin Haas as chief development and technology officer - marketscreener.com
Veracyte Names Kevin Haas As Chief Development And Technology Officer - TradingView
Veracyte Appoints Kevin Haas as Chief Technology Leader - TipRanks
Veracyte Appoints Kevin Haas as Chief Development and Technology Officer - marketscreener.com
Veracyte appoints Kevin Haas as chief development officer - Investing.com
Veracyte (NASDAQ: VCYT) hires Kevin Haas as Chief Development and Technology Officer - Stock Titan
Veracyte, Inc. Appoints Kevin Haas as Chief Development and Technology Officer, Effective March 24, 2026 - marketscreener.com
Iron Triangle Partners LP Purchases New Position in Veracyte, Inc. $VCYT - MarketBeat
Fred Alger Management LLC Takes $26.35 Million Position in Veracyte, Inc. $VCYT - MarketBeat
Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT - MarketBeat
Veracyte, Inc. $VCYT is ArrowMark Colorado Holdings LLC's 7th Largest Position - MarketBeat
Veracyte Inc Stock (ISIN: US92347M1009) Holds Steady Amid Analyst Downgrade and Mixed Signals - AD HOC NEWS
Veracyte (NASDAQ:VCYT) Downgraded by Zacks Research to "Hold" - MarketBeat
Veracyte, Inc. $VCYT Stock Holdings Lifted by First Trust Advisors LP - MarketBeat
Veracyte (VCYT) CAO awarded 10,525 RSUs in new equity grant - Stock Titan
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):